BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Privitera G, Pugliese D, Onali S, Petito V, Scaldaferri F, Gasbarrini A, Danese S, Armuzzi A. Combination therapy in inflammatory bowel disease - from traditional immunosuppressors towards the new paradigm of dual targeted therapy. Autoimmun Rev 2021;20:102832. [PMID: 33866066 DOI: 10.1016/j.autrev.2021.102832] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Adamina M, Fiorino G. At the crossroads of caution and intervention: anti-TNF therapy prior to elective CD surgery Authors' Reply to: "Anti-TNF therapy before intestinal surgery for Crohn's disease and the risks of postoperative complications". J Crohns Colitis 2021:jjab092. [PMID: 33999192 DOI: 10.1093/ecco-jcc/jjab092] [Reference Citation Analysis]
2 Zhou C, Zhou H, Zhang F, Hao L, Guo J. Active Ingredients and Potential Mechanisms of the Gan Jiang-Huang Qin-Huang Lian-Ren Shen Decoction against Ulcerative Colitis: A Network Pharmacology and Molecular Docking-Based Study. Evid Based Complement Alternat Med 2021;2021:1925718. [PMID: 34539797 DOI: 10.1155/2021/1925718] [Reference Citation Analysis]
3 Gupta R, Schulberg JD, Niewiadomski O, Wright EK. Combination tacrolimus and ustekinumab therapy is effective in inducing clinical, biochemical and endoscopic remission in refractory moderate to severe ulcerative colitis. Autoimmun Rev 2022;:103115. [PMID: 35595052 DOI: 10.1016/j.autrev.2022.103115] [Reference Citation Analysis]
4 Antunes JC, Seabra CL, Domingues JM, Teixeira MO, Nunes C, Costa-Lima SA, Homem NC, Reis S, Amorim MTP, Felgueiras HP. Drug Targeting of Inflammatory Bowel Diseases by Biomolecules. Nanomaterials (Basel) 2021;11:2035. [PMID: 34443866 DOI: 10.3390/nano11082035] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
5 Pugliese D, Privitera G, Fiorani M, Parisio L, Calvez V, Papa A, Gasbarrini A, Armuzzi A. Targeting IL12/23 in ulcerative colitis: update on the role of ustekinumab. Therap Adv Gastroenterol 2022;15:17562848221102283. [PMID: 35721840 DOI: 10.1177/17562848221102283] [Reference Citation Analysis]
6 Retnakumar SV, Geesala R, Bretin A, Tourneur-Marsille J, Ogier-Denis E, Maretzky T, Thu Nguyen HT, Muller S. Targeting the endo-lysosomal autophagy pathway to treat inflammatory bowel diseases. J Autoimmun 2022;128:102814. [PMID: 35298976 DOI: 10.1016/j.jaut.2022.102814] [Reference Citation Analysis]
7 Zakerska-banaszak O, Łykowska-szuber L, Walczak M, Żuraszek J, Zielińska A, Skrzypczak-zielińska M. Cytotoxicity of Thiopurine Drugs in Patients with Inflammatory Bowel Disease. Toxics 2022;10:151. [DOI: 10.3390/toxics10040151] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Privitera G, Pugliese D, Lopetuso LR, Scaldaferri F, Papa A, Rapaccini GL, Gasbarrini A, Armuzzi A. Orphan patients with inflammatory bowel disease - when we treat beyond evidence. World J Gastroenterol 2021; 27(47): 8047-8057 [DOI: 10.3748/wjg.v27.i47.8047] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]